{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"12.2","value":"5"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Thrombotic microangiopathy (TMA)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"19.2","value":"10"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"8.2","value":"2.5"}]}],"title":"Hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"TMA is defined as (Ho et al., 2005):\n\n1. RBC fragmentation and \\>2 schistocytes per high-power field on peripheral smear\n2. Concurrent increased serum LDH above institutional baseline\n3. Concurrent renal and/or neurologic dysfunction without other explanation\n4. Negative direct and indirect Coombs test results A cumulative incidence will be computed along with a 90% CI.\n\nVOD/SOS is defined as: In the first 20 days after HCT, the presence of ≥2 of the following: 1. Bilirubin \\>2 mg/Dl, 2. Hepatomegaly or pain in right upper quadrant, 3. Weight gain (\\>2% basal weight).\n\nA cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"365 days post transplant","title":"Cumulative Incidences of Thrombotic Microangiopathy (TMA) and Hepatic Veno-occlusive Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}